Research programme: cationic therapeutics - Immtech

Drug Profile

Research programme: cationic therapeutics - Immtech

Alternative Names: Aromatic cations - Immtech; DAP 075; DB-75

Latest Information Update: 24 Sep 2010

Price : $50

At a glance

  • Originator Auburn University; Duke University; Georgia State University; University of North Carolina at Chapel Hill
  • Developer Immtech Pharmaceuticals
  • Class Amidines; Benzamidines
  • Mechanism of Action DNA inhibitors; Imidazoline receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Bacterial infections; Mycoses
  • Discontinued Alzheimer's disease; Cancer; Diabetes mellitus; Tuberculosis

Most Recent Events

  • 31 Mar 2009 Discontinued - Preclinical for Tuberculosis in USA (PO)
  • 31 Mar 2009 Discontinued - Preclinical for Diabetes mellitus in USA (PO)
  • 31 Mar 2009 Discontinued - Preclinical for Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top